Comparative Pharmacology
Head-to-head clinical analysis: MD 50 versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 50 versus RENOGRAFIN 76.
MD-50 vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiographic contrast agent that attenuates X-rays due to its high iodine content, allowing visualization of vascular structures and organs during imaging. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
300 mg intravenously every 12 hours.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours (normal renal function). In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 24-36 hours, necessitating dose adjustment. For contrast media, the half-life determines the window for imaging procedures.
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal excretion of unchanged drug (90-95%) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent